- Home
- SCNI vs TCBP Comparison
SCNI vs TCBP Comparison
Compare SCNI & TCBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCNI
- TCBP
- Stock Information
- Founded
- SCNI 2003
- TCBP 2013
- Country
- SCNI Israel
- TCBP United Kingdom
- Employees
- SCNI N/A
- TCBP N/A
- Industry
- SCNI Biotechnology: Biological Products (No Diagnostic Substances)
- TCBP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SCNI Health Care
- TCBP Health Care
- Exchange
- SCNI Nasdaq
- TCBP Nasdaq
- Market Cap
- SCNI 3.5M
- TCBP 3.0M
- IPO Year
- SCNI N/A
- TCBP 2022
- Fundamental
- Price
- SCNI $3.48
- TCBP $0.70
- Analyst Decision
- SCNI
- TCBP Strong Buy
- Analyst Count
- SCNI 0
- TCBP 1
- Target Price
- SCNI N/A
- TCBP $3.00
- AVG Volume (30 Days)
- SCNI 13.2K
- TCBP 378.6K
- Earning Date
- SCNI 11-22-2024
- TCBP 02-09-2025
- Dividend Yield
- SCNI N/A
- TCBP N/A
- EPS Growth
- SCNI N/A
- TCBP N/A
- EPS
- SCNI 8.20
- TCBP N/A
- Revenue
- SCNI $452,000.00
- TCBP N/A
- Revenue This Year
- SCNI N/A
- TCBP N/A
- Revenue Next Year
- SCNI N/A
- TCBP N/A
- P/E Ratio
- SCNI $0.42
- TCBP N/A
- Revenue Growth
- SCNI N/A
- TCBP N/A
- 52 Week Low
- SCNI $2.23
- TCBP $0.44
- 52 Week High
- SCNI $8.92
- TCBP $41.50
- Technical
- Relative Strength Index (RSI)
- SCNI 56.32
- TCBP 35.27
- Support Level
- SCNI $3.20
- TCBP $0.45
- Resistance Level
- SCNI $3.55
- TCBP $0.70
- Average True Range (ATR)
- SCNI 0.18
- TCBP 0.08
- MACD
- SCNI 0.03
- TCBP 0.09
- Stochastic Oscillator
- SCNI 51.72
- TCBP 48.81
About SCNI Scinai Immunotherapeutics Ltd.
Scinai Immunotherapeutics Ltd is a biopharmaceutical company focused on developing, manufacturing and commercializing products for the prevention and treatment of infectious diseases and other illnesses. It has executed eight clinical trials in seven countries, around 12,400 participants in the Phase 3 trial of its vaccine candidate and has built a GMP biologics manufacturing facility for biopharmaceutical products. The company is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with a nanosized antibody (NanoAb) pipeline.
About TCBP TC BioPharm (Holdings) plc
TC BioPharm (Holdings) PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapy products that are based on its proprietary allogeneic gamma delta T (abbreviated as GD-T) cell platform. Harnessing the innate ability of GD-Ts has enabled the company to develop a range of clinical-stage cell therapies designed to combat cancer and viral infection.